Mirum Pharmaceuticals Inc (MIRM)
44.50
-1.76
(-3.80%)
USD |
NASDAQ |
Nov 15, 16:00
44.45
-0.05
(-0.11%)
After-Hours: 20:00
Mirum Pharmaceuticals Research and Development Expense (TTM): 121.95M for June 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 121.95M |
| March 31, 2024 | 111.28M |
| December 31, 2023 | 102.61M |
| September 30, 2023 | 102.78M |
| June 30, 2023 | 102.88M |
| March 31, 2023 | 106.30M |
| December 31, 2022 | 106.84M |
| September 30, 2022 | 103.51M |
| June 30, 2022 | 107.77M |
| March 31, 2022 | 117.38M |
| Date | Value |
|---|---|
| December 31, 2021 | 131.43M |
| September 30, 2021 | 133.38M |
| June 30, 2021 | 118.89M |
| March 31, 2021 | 102.40M |
| December 31, 2020 | 81.60M |
| September 30, 2020 | 66.26M |
| June 30, 2020 | 62.43M |
| March 31, 2020 | 55.47M |
| December 31, 2019 | 42.99M |
| September 30, 2019 | 28.61M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
42.99M
Minimum
Dec 2019
133.38M
Maximum
Sep 2021
98.85M
Average
103.51M
Median
Sep 2022
Research and Development Expense (TTM) Benchmarks
| Arcutis Biotherapeutics Inc | 85.72M |
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 114.20M |
| MannKind Corp | 43.99M |
| TG Therapeutics Inc | 87.86M |